MARKET

KALA

KALA

Kala Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.04
-0.08
-1.31%
Closed 16:41 02/26 EST
OPEN
6.12
PREV CLOSE
6.12
HIGH
6.15
LOW
5.95
VOLUME
561.51K
TURNOVER
--
52 WEEK HIGH
8.98
52 WEEK LOW
3.240
MARKET CAP
222.30M
P/E (TTM)
-2.1885
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KALA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KALA stock price target is 18.33 with a high estimate of 51.00 and a low estimate of 7.00.

EPS

KALA News

More
  • Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  • Business Wire · 6d ago
  • Kala Pharmaceuticals: Solid Progress
  • Seeking Alpha - Article · 02/17 17:57
  • Kala Pharmaceuticals EPS misses by $0.03, misses on revenue
  • seekingalpha · 02/12 17:06
  • Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 02/12 16:38

Industry

Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.43%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About KALA

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
More

Webull offers kinds of Kala Pharmaceuticals Inc stock information, including NASDAQ:KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions.